Searchable abstracts of presentations at key conferences in endocrinology

ea0022oc4.1 | Adrenals | ECE2010

Subtype differentiation in primary hyperaldosteronism: evaluation of alternative algorithms avoiding a controversial gold standard

Lang Katharina , Hahner Stefanie , Vonend O , Rump L C , Quninkler M , Diederich Sven , Maier Katharina , Beuschlein Felix , Bidlingmaier Martin , Endres S , Engelke C , Kickuth Ralph , Fassnacht Martin , Reincke Martin , Allolio Bruno

Context: Primary aldosteronism (PHA) is the most common cause of secondary hypertension. Distinguishing unilateral (UAH) from bilateral (BAH) and other causes of PHA is one of the greatest challenges in the diagnostic process. Adrenal venous sampling (AVS) is widely considered to be the gold standard for subtype differentiation.Methods: Technical and diagnostic outcome of AVS was analysed retrospectively in 59 patients with PHA who underwent AVS at the U...

ea0016p333 | Endocrine tumours | ECE2008

Deficits in the clinical management of patients with adrenocortical carcinoma in Germany

Johanssen Sarah , Koschker Ann-Cathrin , Hahner Stefanie , Quinkler Marcus , Saeger Wolfgang , Morcos Michael , Willenberg Holger , Langer Peter , Klose Silke , Reisch Nicole , Beuschlein Felix , Brauckhoff Michael , Fottner Christian , Wortmann Sebastian , Oelkers Wolfgang , Maeder Uwe , Fassnacht Martin , Allolio Bruno

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Accordingly, in many cases, the attending doctors have no previous experience with the disease. The aim of our study was to evaluate the quality of care in a large number of patients with ACC in Germany. Data from 263 adult patients of the German ACC registry were analyzed with regard to the following parameters: time to diagnosis, hormonal assessment, imaging, histopathological documentation, follow-up. The...

ea0099rc3.5 | Rapid Communications 3: Adrenal and Cardiovascular Endocrinology | Part I | ECE2024

The saline infusion test with mass spectrometric measurements of aldosterone in patients tested for primary aldosteronism

Pamporaki Christina , Remde Hanna , Constantinescu Georgiana , Kuerzinger Lydia , Fuss Carmina Teresa , Peitzsch Mirko , Schulze Manuel , Lee Myron , Yang Jun , Mueller Lisa , Williams Tracy Ann , Reincke Martin , Gruber Sven , Beuschlein Felix , Lenders Jacques , Eisenhofer Graeme

Background: Confirmation of primary aldosteronism (PA) with the saline infusion test (SIT) requires accurate measurements of plasma aldosterone, best achieved by mass spectrometry. Performance of the test and appropriate cut-offs remain inadequately defined.Design and methods: This prospective multicenter cohort study involved 451 patients with suspected PA who underwent a seated SIT. Among these, there were 90 and 76 in whom PA was respectively confirmed and excluded based on...

ea0099p16 | Adrenal and Cardiovascular Endocrinology | ECE2024

False-positive and false-negative results during screening, confirmatory testing and subtyping for suspected primary aldosteronism: lessons from Prosaldo

Constantinescu Andreea Georgiana , Pamporaki Christina , Alessi Francesco , Passauer Jens , Remde Hanna , Kuerzinger Lydia , Fuss CarminaTeresa , Schulze Manuel , Peitzsch Mirko , Horvath Andrea , Yang Jun , Bruedgam Denise , Williams TracyAnn , Reincke Martin , Gruber Sven , Beuschlein Felix , Lenders Jacques , Eisenhofer Graeme

Background: Diagnostic stratification of patients with suspected primary aldosteronism (PA) is a multistep process reliant on tests that are not infallible. Only through prospective studies can diagnostic accuracy be appropriately assessed.Methods: The PROSALDO trial enrolled 819 patients between 2019 and 2023 to assess steroid profiles against routine tests for diagnostic stratification. A combination of these tests and outcome assessments, including me...

ea0081oc1.3 | Oral Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Canakinumabin patients with COVID-19 and type 2 diabetes (CanCovDia) – a multicentric, randomised, double-blind, placebo-controlled phase 3 trial

Hepprich Matthias , Mudry Jonathan , Gregoriano Claudia , Jornayvaz Francois R , Carballo Sebastian , Wojtusciszyn Anne , Bart Pierre-Alexandre , Chiche Jean-Daniel , Fischli Stefan , Baumgartner Thomas , Cavelti-Weder Claudia , Beuschlein Felix , Braun Dominque L , Gunthard Huldrych F , West Emily , Conen Anna , Isenring Egon , Bucklar Gabriela , Aubry Yoann , Dey Ludovic , Muller Beat , Schutz Philipp , Cattaneo Marco , Hunziker Patrick , Donath Marc Y

Background: Patients with type 2 diabetes and overweight have a chronic activation of the innate immune system possibly explaining the increased risk of a hyperinflammatory response and severe COVID-19. We aimed to test whether blockade of interleukin-1β(IL-1β) using canakinumab improves clinical outcome.Methods: CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-o...

ea0081oc13.6 | Oral Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Machine Learning models for the accurate prediction of malignant pheochromocytomas and paragangliomas

Pamporaki Christina , Berends Annika MA , Filippatos Angelos , Prodanov Tamara , Meuter Leah , Prejbisz Aleksander , Beuschlein Felix , Fassnacht Martin , Timmers Henri , Noelting Svenja , Abhyankar Kaushik Ganesh , Contsantinescu Georgiana , Kunath Carola , Wang Katharina , Remde Hanna , Januszewicz Andrzej , Robledo Mercedes , Lenders Jacques , Kerstens Michiel , Pacak Karel , Eisenhofer Graeme

Introduction: Pheochromocytomas and paragangliomas (PPGLs) exhibit an up to 20% malignancy rate. Various clinical, genetic, and pathological features have been proposed as predictors of malignancy. However, until present there are no robust indices to reliably predict metastatic PPGLs.Aim: The aim of the present study was to prospectively validate the value of methoxytyramine as risk marker of metastatic disease and establish a machine learning (ML) mode...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0090oc3.1 | Oral Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Diagnosing Vasopressin Deficiency (Central Diabetes Insipidus) using Copeptin following Hypertonic Saline and Arginine Stimulation

Refardt Julie , Atila Cihan , Chifu Irina , Ferrante Emanuele , Erlic Zoran , Drummond Juliana , Mantovani Beatrice , Drexhage Roos , Odilia Sailer Clara , Widmer Andrea , Felder Susan , Powlson Andrew , Hutter Nina , Vogt Deborah , Gurnell Mark , Soares Beatriz Santana , Hofland Hans , Beuschlein Felix , Fassnacht Martin , Winzeler Bettina , Christ-Crain Mirjam

Background: The main challenge in the diagnosis of arginine vasopressin deficiency (AVP-deficiency, formerly known as central diabetes insipidus), is its distinction against primary polydipsia. Hypertonic saline stimulated copeptin showed a high diagnostic accuracy of 97% in distinguishing between AVP-deficiency and primary polydipsia (Fenske W, Refardt J, NEJM 2018), but comprises discomfort for patients and requires close sodium monitoring. Arginine stimulated copeptin showe...

ea0065ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2019

Urine steroid metabolome analysis allows for metabolic risk stratification in 1309 prospectively recruited patients with benign adrenal tumours and different degrees of cortisol excess

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urszula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe Astrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , O'Reilly Michael W , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Benign adrenal tumours (AT) can be non-functioning (NFAT) or associated with cortisol excess, as indicated by failure to suppress serum morning cortisol to <50 nmol/l in the 1mg-dexamethasone suppression test (1 mg-DST). The latter group divides into patients with clinically overt signs of cortisol excess (adrenal Cushing’s syndrome, CUSH) and patients lacking CUSH signs (mild autonomous cortisol excess, MACE). Smaller series and a recent meta-analysis rep...